Cargando…

P-017: POINT-OF-CARE DIAGNOSTIC FOR QUANTIFICATION OF FOETAL HAEMOGLOBIN (HB F) LEVELS IN MONITORING HYDROXYUREA THERAPY FOR CHILDREN WITH SICKLE CELL DISEASE (SCD) IN GHANA

Detalles Bibliográficos
Autores principales:	C., SEGBEFIA, Y., DEI-ADOMAKOH, E., MENSAH, P., THOTA, I., ODAME
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Poster Presentations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9426818/ http://dx.doi.org/10.1097/01.HS9.0000872968.02648.ef

Ejemplares similares

S129: IMPLEMENTATION OF HYDROXYUREA THERAPY FOR SICKLE CELL DISEASE ON A LARGE SCALE IN GHANA
por: Ohene-Frempong, K, et al.
Publicado: (2022)

FOETAL HAEMOGLOBIN (HbF) STATUS IN ADULT SICKLE CELL ANAEMIA PATIENTS IN IBADAN, NIGERIA
por: Olaniyi, J.A., et al.
Publicado: (2010)

Foetal Haemoglobin, Erythrocytes Containing Foetal Haemoglobin, and Hematological Features in Congolese Patients with Sickle Cell Anaemia
por: Tshilolo, L., et al.
Publicado: (2012)

Prospective identification of variables as outcomes for treatment (PIVOT): study protocol for a randomised, placebo-controlled trial of hydroxyurea for Ghanaian children and adults with haemoglobin SC disease
por: Smart, Luke R., et al.
Publicado: (2023)

P-003: EVALUATION OF TREATMENT PATTERN, HEALTHCARE RESOURCE UTILIZATION AND COSTS OF ILLNESS FOR SICKLE CELL DISEASE IN GHANA: A PRIVATE MEDICAL INSURANCE CLAIMS DATABASE STUDY
por: Y., DEI-ADOMAKOH, et al.
Publicado: (2022)

High Foetal Haemoglobin in Sickle Cell Disease: Not so Protective?
por: Conran, Nicola
Publicado: (2015)

P-047: PROSPECTIVE IDENTIFICATION OF VARIABLES AS OUTCOMES FOR TREATMENT (PIVOT): A PHASE II CLINICAL TRIAL OF HYDROXYUREA FOR CHILDREN AND ADULTS WITH HBSC DISEASE
por: L., SMART, et al.
Publicado: (2022)

Foetal Haemoglobin and Disease Severity in Nigerian Children with Sickle Cell Anaemia
por: Adeodu, Oluwagbemiga O., et al.
Publicado: (2017)

Foetal haemoglobin and disease severity in sickle cell anaemia patients in Kampala, Uganda
por: Mpalampa, Lena, et al.
Publicado: (2012)

P-002: MULTISPECTRAL IMAGING FOR MICROCHIP ELECTROPHORESIS ENABLES POINT-OF-CARE NEWBORN HEMOGLOBIN VARIANT SCREENING
por: R., AN, et al.
Publicado: (2022)

Evaluation of treatment patterns, healthcare resource utilization and cost of illness for sickle cell disease in Ghana: a private medical insurance claims database study
por: Marfo, Kwaku, et al.
Publicado: (2023)

Multispectral imaging for MicroChip electrophoresis enables point-of-care newborn hemoglobin variant screening
por: An, Ran, et al.
Publicado: (2022)

Burden of Sickle Cell Disease in Ghana: The Korle-Bu Experience
por: Asare, Eugenia V., et al.
Publicado: (2018)

Negative Epistasis between Sickle and Foetal Haemoglobin Suggests a Reduction in Protection against Malaria
por: Mmbando, Bruno P., et al.
Publicado: (2015)

Foetal haemoglobin and the dynamics of paediatric malaria
por: Billig, Erica MW, et al.
Publicado: (2012)

Role of microRNA in hydroxyurea mediated HbF induction in sickle cell anaemia patients
por: Kargutkar, Neha, et al.
Publicado: (2023)

Significantly elevated foetal haemoglobin levels in individuals with glucose 6-phosphate dehydrogenase disease and/or sickle cell trait: a cross-sectional study in Cape Coast, Ghana
por: Adu, Patrick, et al.
Publicado: (2017)

Outcome of Hydroxyurea Use in SCD and Evaluation of Patients’ Perception and Experience in Nigeria
por: Chianumba, Reuben Ikechukwu, et al.
Publicado: (2022)

Lung Function Abnormalities in Sickle Cell Anaemia
por: Dei-Adomakoh, Yvonne A., et al.
Publicado: (2019)

The Effects of Treatment with Blood Transfusion, Iron Chelation and Hydroxyurea on Puberty, Growth and Spermatogenesis in Sickle Cell Disease (SCD): A short update
por: Soliman, Ashraf T, et al.
Publicado: (2021)

Association Between Selected Single Nucleotide Polymorphisms in Globin and Related Genes and Response to Hydroxyurea Therapy in Ghanaian Children with Sickle Cell Disease
por: Manu, Gloria Pokuaa, et al.
Publicado: (2022)

Sickle haemoglobin, haemoglobin C and malaria mortality feedbacks
por: Gonçalves, Bronner P., et al.
Publicado: (2016)

Hydroxyurea Treatment for Sickle Cell Disease
por: Steinberg, Martin H.
Publicado: (2002)

Hydroxyurea decreases hospitalizations in pediatric patients with Hb SC and Hb SB+ thalassemia
por: Lebensburger, Jeffrey D, et al.
Publicado: (2015)

Enhanced Hypercoagulability in Sickle Cell Anaemia Patients with Chronic Leg Ulcers
por: Sackey, David, et al.
Publicado: (2020)

Labile glycated haemoglobin and carbamylated haemoglobin are still critical points for HbA(1c) measurement
por: Desmons, Aurore, et al.
Publicado: (2017)

Postnatal temporal changes of foetal haemoglobin in prematurely born infants
por: Bednarczuk, Nadja, et al.
Publicado: (2022)

Most adults with severe HbSC disease are not treated with hydroxyurea
por: Ghunney, William Kwesi, et al.
Publicado: (2023)

P-042: POPULATION PHARMACOKINETICS AND PHARMACODYNAMICS ANALYSIS OF HYDROXYUREA, IN ADULT PATIENTS WITH SICKLE CELL DISEASE (SCD) RECEIVING BOTH TABLETS OR CAPSULES FORMULATIONS, AND EVALUATION OF DISEASE MARKERS
por: P., BARTOLUCCI, et al.
Publicado: (2022)

Hydroxyurea and sickle cell anemia: effect on quality of life
por: Ballas, Samir K, et al.
Publicado: (2006)

Effective control of sickle cell disease with hydroxyurea therapy
por: Singh, Harminder, et al.
Publicado: (2010)

The influence of hydroxyurea on oxidative stress in sickle cell anemia
por: Torres, Lidiane de Souza, et al.
Publicado: (2012)

Evaluation of hydroxyurea genotoxicity in patients with sickle cell disease
por: de Oliveira, Emanuel Almeida Moreira, et al.
Publicado: (2019)

Immunophenotypic characterisation of non-Hodgkin lymphomas at a tertiary hospital in Ghana
por: Adomako, Joseph, et al.
Publicado: (2022)

Hydroxyurea Therapy for Children With Sickle Cell Anemia in Sub‐Saharan Africa: Rationale and Design of the REACH Trial
por: McGann, Patrick T., et al.
Publicado: (2015)

Fetal‐haemoglobin enhancing genotype at BCL11A reduces HbA(2) levels in patients with sickle cell anaemia
por: Adeyemo, Titilope A., et al.
Publicado: (2021)

ENHANCE—(Electronic Hydroxyurea Adherence): A Protocol to Increase Hydroxyurea Adherence in Patients with Sickle Cell Disease
por: Creary, Susan, et al.
Publicado: (2016)

Soluble haemoglobin scavenger receptor (sCD163): a marker associated with bacteraemia
por: Gaïni, S, et al.
Publicado: (2005)

World Coalition on SCD launches, sparking global focus on SCD diagnosis and care
por: Zapfel, Andrew, et al.
Publicado: (2023)

The burden and quality of life of caregivers of sickle cell anemia patients taking hydroxyurea versus those not taking hydroxyurea
por: da Silva, Luiz Bernardino Lima, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_jvaocp5vokt7cd1fdj8hq7h7bd